ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 869

UBE2L3 genotype Influences Plasma Cell Proliferation in Systemic Lupus Erythematosus By Regulation of NF-κB By the Linear Ubiquitination Assembly Complex

Myles J. Lewis1, Simon Vyse1, Adrian M. Shields2, Sebastian Boeltz2, Patrick Gordon3, Timothy D. Spector4, Paul J. Lehner5, Henning Walczak6 and Timothy J. Vyse2, 1Experimental Medicine & Rheumatology, Queen Mary University of London, London, United Kingdom, 2Medical & Molecular Genetics, King's College London, London, United Kingdom, 3Department of Rheumatology, King's College London, London, United Kingdom, 4Department of Twin Research, King's College London, London, United Kingdom, 5Cambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom, 6Centre for Cell Death, Cancer and Inflammation, University College London, London, United Kingdom

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Functional Genomics, plasma cells and systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Title: Systemic Lupus Erythematosus - Human Etiology and Pathogenesis I: Pathways of Inflammation/Injury

Session Type: Abstract Submissions (ACR)

Background/Purpose: Genome-wide association studies have identified a strong association between a single risk haplotype of the UBE2L3gene and Systemic Lupus Erythematosus (SLE), as well as multiple autoimmune diseases (rheumatoid arthritis, juvenile idiopathic arthritis, inflammatory bowel disease, psoriasis). UBE2L3 is an E2 ubiquitin-conjugating enzyme specific for RING/HECT hybrid or HECT E3 ligases. Linear ubiquitination is a newly described form of ubiquitination, whose only known function is controlling activation of NF-kB, mediated by the linear ubiquitination chain assembly complex (LUBAC).

Methods: UBE2L3 genotype data from GWAS in SLE was imputed up to 1000 Genomes level. UBE2L3 function was studied in vitro using standard molecular biology techniques in HEK293 cells, or ex vivo using B cells and/or monocytes from healthy individuals or SLE patients (NF-kB translocation by Imagestream, multicolour flow cytometry of B cell subsets) stratified by UBE2L3genotype.

Results: Data from SLE GWAS, imputed to 1000 Genomes level identified rs140490 as the most strongly associated UBE2L3 SNP, located at -270bp of the promoter region (P=8.6×10-14; OR 1.30, 95%CI: 1.21-1.39). Microarray /western blot studies found that the rs140490 risk allele increased UBE2L3 expression in B cells and monocytes from PBMC. Overexpression of UBE2L3 in combination with LUBAC in HEK293-NF-kB reporter cell line led to a marked upregulation in NF-kB activity, which was abolished by dominant-negative mutant UBE2L3[C86S]. RNAi blockade of UBE2L3 antagonised TNF signalling by inhibiting IκBα processing. Ex vivo human B cells and monocytes were isolated from genotyped healthy twins stimulated with CD40L or TNF respectively and NF-kB translocation quantified by Imagestream analysis. rs140490 genotype was correlated with both basal NF-kB activation in healthy human individuals, as well as the sensitivity of NF-kB to CD40 stimulation in B cells and TNF stimulation in monocytes. UBE2L3 expression was 3-4-fold elevated in peripheral blood plasmablasts and plasma cells (P<0.0001), with increased UBE2L3 expression in plasma cells from SLE patients compared to controls (P=0.01). UBE2L3 expression was significantly elevated in Ki-67+ B cells consistent with a functional role in B cell proliferation. Consistent with the functional effect of UBE2L3 on CD40 driven NF-kB activation in human B cells, rs140490 genotype correlated with increasing plasmablast and plasma cell differentiation in SLE patients (P<0.001).

Conclusion: Our study is the first to show that the UBE2L3 risk haplotype exerts a critical rate-limiting effect on TNF and CD40 activation of NF-kB in primary human cells, and that this effect is mediated through LUBAC. By tracking NF-kB nuclear translocation in B cells and monocytes from genotyped individuals, we have shown that the UBE2L3 risk variant amplifies both basal NF-kB activation and sensitivity of NF-kB to stimulation in ex vivo cells, leading to increased plasma cell proliferation in SLE.


Disclosure:

M. J. Lewis,
None;

S. Vyse,
None;

A. M. Shields,
None;

S. Boeltz,
None;

P. Gordon,
None;

T. D. Spector,
None;

P. J. Lehner,
None;

H. Walczak,
None;

T. J. Vyse,
None.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/ube2l3-genotype-influences-plasma-cell-proliferation-in-systemic-lupus-erythematosus-by-regulation-of-nf-%ce%bab-by-the-linear-ubiquitination-assembly-complex/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology